Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/CALD1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CALD1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/CALD1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CALD1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CALD1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CALD1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CALD1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CALD1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CALD1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CALD1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000701519 | Prostate | Tumor | actin filament organization | 142/3246 | 442/18723 | 1.40e-14 | 1.89e-12 | 142 |
GO:005101719 | Prostate | Tumor | actin filament bundle assembly | 63/3246 | 157/18723 | 1.18e-11 | 9.07e-10 | 63 |
GO:006157219 | Prostate | Tumor | actin filament bundle organization | 63/3246 | 161/18723 | 4.23e-11 | 2.82e-09 | 63 |
GO:000301214 | Prostate | Tumor | muscle system process | 105/3246 | 452/18723 | 7.44e-04 | 5.14e-03 | 105 |
GO:000701528 | Skin | AK | actin filament organization | 85/1910 | 442/18723 | 5.94e-09 | 4.14e-07 | 85 |
GO:005101728 | Skin | AK | actin filament bundle assembly | 36/1910 | 157/18723 | 2.48e-06 | 6.76e-05 | 36 |
GO:006157228 | Skin | AK | actin filament bundle organization | 36/1910 | 161/18723 | 4.59e-06 | 1.10e-04 | 36 |
GO:00030129 | Skin | AK | muscle system process | 64/1910 | 452/18723 | 4.32e-03 | 2.52e-02 | 64 |
GO:000701529 | Skin | cSCC | actin filament organization | 156/4864 | 442/18723 | 7.37e-06 | 1.02e-04 | 156 |
GO:005101729 | Skin | cSCC | actin filament bundle assembly | 60/4864 | 157/18723 | 4.86e-04 | 3.66e-03 | 60 |
GO:006157229 | Skin | cSCC | actin filament bundle organization | 60/4864 | 161/18723 | 1.02e-03 | 6.86e-03 | 60 |
GO:000701530 | Thyroid | HT | actin filament organization | 50/1272 | 442/18723 | 2.71e-04 | 3.73e-03 | 50 |
GO:005101730 | Thyroid | HT | actin filament bundle assembly | 23/1272 | 157/18723 | 3.91e-04 | 4.90e-03 | 23 |
GO:006157230 | Thyroid | HT | actin filament bundle organization | 23/1272 | 161/18723 | 5.63e-04 | 6.62e-03 | 23 |
GO:000301210 | Thyroid | HT | muscle system process | 48/1272 | 452/18723 | 1.41e-03 | 1.34e-02 | 48 |
GO:0007015112 | Thyroid | PTC | actin filament organization | 225/5968 | 442/18723 | 3.76e-17 | 3.44e-15 | 225 |
GO:0051017112 | Thyroid | PTC | actin filament bundle assembly | 83/5968 | 157/18723 | 3.73e-08 | 8.18e-07 | 83 |
GO:0061572112 | Thyroid | PTC | actin filament bundle organization | 84/5968 | 161/18723 | 6.75e-08 | 1.40e-06 | 84 |
GO:0007015210 | Thyroid | ATC | actin filament organization | 227/6293 | 442/18723 | 5.96e-15 | 3.85e-13 | 227 |
GO:0051017210 | Thyroid | ATC | actin filament bundle assembly | 85/6293 | 157/18723 | 8.99e-08 | 1.54e-06 | 85 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CALD1 | SNV | Missense_Mutation | | c.1384N>A | p.Glu462Lys | p.E462K | Q05682 | protein_coding | deleterious_low_confidence(0.05) | possibly_damaging(0.732) | TCGA-A2-A0EX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
CALD1 | SNV | Missense_Mutation | | c.56N>A | p.Arg19Gln | p.R19Q | Q05682 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
CALD1 | SNV | Missense_Mutation | | c.1315N>C | p.Glu439Gln | p.E439Q | Q05682 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.898) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
CALD1 | SNV | Missense_Mutation | | c.1450C>G | p.Arg484Gly | p.R484G | Q05682 | protein_coding | tolerated(0.24) | benign(0) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
CALD1 | SNV | Missense_Mutation | | c.232N>A | p.Glu78Lys | p.E78K | Q05682 | protein_coding | deleterious(0.01) | possibly_damaging(0.652) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CALD1 | SNV | Missense_Mutation | novel | c.1622N>T | p.Arg541Leu | p.R541L | Q05682 | protein_coding | deleterious(0) | possibly_damaging(0.845) | TCGA-B6-A1KI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CALD1 | SNV | Missense_Mutation | | c.2026N>C | p.Asp676His | p.D676H | Q05682 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D8-A1J9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CALD1 | SNV | Missense_Mutation | novel | c.1065N>T | p.Glu355Asp | p.E355D | Q05682 | protein_coding | tolerated_low_confidence(0.37) | benign(0.096) | TCGA-E9-A54Y-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CALD1 | SNV | Missense_Mutation | novel | c.2128N>G | p.Arg710Gly | p.R710G | Q05682 | protein_coding | deleterious(0.01) | probably_damaging(0.992) | TCGA-JL-A3YW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CALD1 | SNV | Missense_Mutation | novel | c.2090C>T | p.Pro697Leu | p.P697L | Q05682 | protein_coding | deleterious(0) | possibly_damaging(0.874) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |